Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1995-10-5
|
| pubmed:abstractText |
Pentasa is a controlled-release tablet made from semipermeable microspheres and designed to continuously deliver therapeutic quantities of 5-ASA (5-aminosalicylic acid) throughout the gastrointestinal tract. Scintigraphic studies in healthy subjects have documented that 5-ASA release could occur in the small intestine. We tested here the disintegration of Pentasa in the digestive tract of nine patients with Crohn's disease of the small intestine.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0269-2813
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
315-20
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:7654894-Adult,
pubmed-meshheading:7654894-Aminosalicylic Acids,
pubmed-meshheading:7654894-Crohn Disease,
pubmed-meshheading:7654894-Humans,
pubmed-meshheading:7654894-Mesalamine,
pubmed-meshheading:7654894-Middle Aged,
pubmed-meshheading:7654894-Samarium,
pubmed-meshheading:7654894-Tablets
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine.
|
| pubmed:affiliation |
Hôpital Saint-Luc, Montréal, Québec, Canada.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|